Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
80 Results for "
α-synuclein aggregation
" in MedChemExpress (MCE) Product Catalog:
Products (80)
80 Results for "α-synuclein aggregation" in MCE Product Catalog:
Cat. No.: HY-121252S
Cat. No.: HY-159945
Target:
Research Areas:
Tau Protein/α-synuclein-IN-2 (Compound 14T) is a blood-brain barrier penetrating tau and α-syn inhibitor. Through its thiourea linker structure, Tau Protein/α-synuclein-IN-2 dose-dependently reduces α-syn oligomerization. In biosensor cells, Tau Protein/α-synuclein-IN-2 prevents the seeding effect of tau aggregation. In the M17D neuroblastoma model, Tau Protein/α-synuclein-IN-2 exhibits anti-inclusion effects. Additionally, Tau Protein/α-synuclein-IN-2 reduces Aβ plaque formation. Tau Protein/α-synuclein-IN-2 holds promise for Alzheimer's disease and Parkinson's disease research.
Cat. No.: HY-W010041R
CAS No.: 488-59-5
Category:
Target:
Cat. No.: HY-W707693
CAS No.: 115268-26-3
Cat. No.: HY-D0914A
CAS No.: 25738-40-3
Cat. No.: HY-186234
CAS No.: 2648041-95-4
Target:
Research Areas:
α-Synuclein aggregate binder 3 is a probe for α-synuclein aggregates. The Ki value of α-Synuclein aggregate binder 3 for binding to sonicated α-synuclein fibrils is 0.8 nM. α-Synuclein aggregate binder 3 can be used for α-synuclein imaging, as well as for detecting disorders associated with α-synuclein aggregation, such as Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy .
Cat. No.: HY-W017370R
CAS No.: 99-48-9
Cat. No.: HY-184816
CAS No.: 2883627-65-2
Research Areas:
α-Synuclein-IN-21 is an α-synuclein (α-Syn) aggregation inhibitor with an IC50 of 1.6 μM. α-Synuclein-IN-21 stabilizes the secondary conformation of α-synuclein monomers, inhibits β-sheet formation, reduces oligonucleation during the aggregation lag phase, dissociates preformed aggregates, and blocks re-aggregation. α-Synuclein-IN-21 reduces α-synuclein inclusions in neuronal cells and scavenges ROS. α-Synuclein-IN-21 can be used for the research of Parkinson's disease .
Cat. No.: HY-178276
CAS No.: 1394328-54-1
Target:
Research Areas:
α-Synuclein-IN-18 (Compound Mol D) is an inhibitor of the autocatalytic proliferation of α-Synuclein aggregate. α-Synuclein-IN-18 can specifically bind to the conserved binding pocket on the surface of α-synuclein fibrils. α-Synuclein-IN-18 can delay the aggregation process of α-synuclein, extend the aggregation T1/2 by three times. α-Synuclein-IN-18 can reduce the generation flux of α-synuclein toxic oligomers, thereby alleviating the neurotoxicity. α-Synuclein-IN-18 can be used for research of Parkinson’sdisease .
Cat. No.: HY-184819
CAS No.: 2883627-56-1
Research Areas:
α-Synuclein-IN-24 is an α-synuclein (α-Syn) aggregation inhibitor with an IC50 of 4.0 μM. α-Synuclein-IN-24 stabilizes the secondary conformation of α-synuclein monomers, inhibits β-sheet formation, reduces oligonucleation during the aggregation lag phase, dissociates preformed aggregates, and blocks reaggregation. α-Synuclein-IN-24 reduces α-synuclein inclusions in neuronal cells and scavenges ROS. α-Synuclein-IN-24 can be used for the research of Parkinson's disease .
Cat. No.: HY-184782
CAS No.: 1026937-99-4
Target:
Research Areas:
α-Synuclein-IN-19 is a polyphenolic acid monoamide derivative and an inhibitor of α-synuclein (α-Syn) aggregation. α-Synuclein-IN-19 can be used in Parkinson's disease-related research .
Cat. No.: HY-W007551
CAS No.: 34698-41-4
Synonyms: 1-Indanamine; 2,3-Dihydro-1H-inden-1-amine
Target:
Research Areas:
1-Aminoindan (1-Indanamine; 2,3-Dihydro-1H-inden-1-amine) is an α-synuclein (α-synuclein) binder. By binding to α-synuclein, 1-Aminoindan promotes the formation of its neuroprotective "cyclic" conformation, thereby reducing the misfolding and aggregation of α-synuclein. 1-Aminoindan is a metabolite of Rasagiline (HY-14605A). 1-Aminoindan can be used in research related to Parkinson's disease .
Cat. No.: HY-184847
CAS No.: 2883627-66-3
Target:
Research Areas:
α-Synuclein-IN-25 is a quinone-acid hybrid and also an α-synuclein aggregation inhibitor with an IC50 of 3.0 μM. α-Synuclein-IN-25 dissociates preformed α-Syn aggregates, inhibits their re-aggregation, scavenges reactive oxygen species, and reduces the formation of α-Syn inclusions in neuronal cells. α-Synuclein-IN-25 can be used in the research of Parkinson's disease .
Cat. No.: HY-184815
CAS No.: 2883627-67-4
Research Areas:
α-Synuclein-IN-20 is an inhibitor of α-synuclein (α-Synuclein) with an IC50 of 4.1 μM against human α-Syn. α-Synuclein-IN-20 exerts anti-aggregation effects by stabilizing the native conformation of α-Syn, inhibiting the formation of β-sheet aggregates and inclusion bodies, and dissociating mature fibrils into functional monomers. α-Synuclein-IN-20 scavenges ROS, protects and repairs dopaminergic neurons, ameliorates Parkinson's disease-like symptoms, and shows low cytotoxicity. α-Synuclein-IN-20 can be used for research related to Parkinson's disease .
Cat. No.: HY-184817
CAS No.: 2883627-63-0
Research Areas:
α-Synuclein-IN-22 is an α-Synuclein inhibitor with an IC50 of 2.7 μM against human α-Syn. α-Synuclein-IN-22 exerts anti-aggregation effects by stabilizing the native conformation of α-Syn, inhibiting the formation of β-sheet aggregates and inclusion bodies, and dissociating mature fibrils into functional monomers. α-Synuclein-IN-22 scavenges ROS and shows low cytotoxicity. α-Synuclein-IN-22 can be used in research related to Parkinson's disease .
Cat. No.: HY-182304
CAS No.: 1338489-62-5
Research Areas:
CLR01 sodium is a blood-brain barrier-permeable anti-aggregation agent. CLR01 sodium inhibits the de novo aggregation of Amyloid-β 40/42, α-synuclein, IAPP, tau protein and SOD1. CLR01 sodium reduces amyloid plaque burden in the cortex of triple-transgenic mice and improves the memory and motor abilities of these mice. CLR01 sodium can be used in research related to Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS) .
Cat. No.: HY-101855R
CAS No.: 882697-00-9
Synonyms: Anle138b (Standard)
Target:
Research Areas:
Emrusolmin (Standard) (Anle138b (Standard)) is the analytical standard of Emrusolmin (HY-101855). This product is intended for research and analytical applications. Emrusolmin (Anle138b), an oligomeric aggregation inhibitor, blocks the formation of pathological aggregates of prion protein (PrPSc) and of α-synuclein (α-syn). Emrusolmin strongly inhibits oligomer accumulation, neuronal degeneration, and disease progression in vivo. Emrusolmin has low toxicity and an excellent oral bioavailability and blood-brain-barrier penetration. Emrusolmin blocks Aβ channels and rescues disease phenotypes in a mouse model for amyloid pathology .
Cat. No.: HY-182893
CAS No.: 1919889-97-6
Research Areas:
SK-129 is a blood-brain barrier-permeable inhibitor of α-synuclein (αS) oligomers with a Kd of 221 nM. SK-129 preferentially binds to neurotoxic αS oligomers over physiological αS monomers, inhibits αS aggregation, blocks the interaction and co-aggregation of αS with tau protein, and prevents the maturation of αS-tau condensates into amyloid aggregates. SK-129 reduces ROS production, rescues dopaminergic neuron degeneration, improves motor function, restores endogenous dopamine synthesis, increases the number of Tyrosine Hydroxylase-positive neurons, prevents brain histopathological changes, alleviates neuroinflammation, and improves survival rates in relevant models. SK-129 can be used in research related to Parkinson's disease (PD) and Lewy body dementia (LBD) .
Cat. No.: HY-114118C
CAS No.: 2924330-56-1
Research Areas:
Cat. No.: HY-153169R
CAS No.: 2754428-18-5
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
